Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: Capecitabine [Xeloda]
Drug: Oxaliplatin
Drug: Trastuzumab [Herceptin]

First Posted Date: 2010-05-26

Last Posted Date: 2015-10-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 36

Registration Number: NCT01130337

Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study

Not Applicable

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Device: Accu-Chek Integra Glucometer

First Posted Date: 2010-05-26

Last Posted Date: 2017-04-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 833

Registration Number: NCT01130480

A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Bevacizumab [Avastin]
Drug: Capecitabine
Drug: Irinotecan

First Posted Date: 2010-05-26

Last Posted Date: 2015-06-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 306

Registration Number: NCT01131078

A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: ibandronate [Bonviva/Boniva]
Drug: alendronate

First Posted Date: 2010-05-21

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 6054

Registration Number: NCT01128257

SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: rituximab

First Posted Date: 2010-05-19

Last Posted Date: 2014-09-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 224

Registration Number: NCT01126541

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Adalimumab
Drug: Placebo to tocilizumab
Drug: Placebo to adalimumab

First Posted Date: 2010-05-10

Last Posted Date: 2013-02-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 326

Registration Number: NCT01119859

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: docetaxel
Drug: pertuzumab
Drug: pertuzumab-placebo
Drug: paclitaxel
Drug: trastuzumab emtansine
Drug: trastuzumab [Herceptin]

First Posted Date: 2010-05-10

Last Posted Date: 2024-03-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1095

Registration Number: NCT01120184

Locations: 🇹🇭
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand
🇹🇷
Gazi Uni Medical Faculty Hospital; Oncology Dept, Ankara, Turkey
🇬🇧
Bristol Haematology and Oncology centre, Bristol, United Kingdom

and more 254 locations

A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas

Phase 2

Completed

Conditions: Brainstem Glioma

Interventions: Drug: Capecitabine
Radiation: Radiation therapy

First Posted Date: 2010-05-06

Last Posted Date: 2014-02-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 45

Registration Number: NCT01118377

A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: RO4917838
Drug: Standard Antipsychotic Therapy

First Posted Date: 2010-05-05

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 29

Registration Number: NCT01116830

A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)

Phase 4

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: rituximab [Mabthera/Rituxan]
Drug: placebo
Drug: methotrexate

First Posted Date: 2010-05-05

Last Posted Date: 2014-03-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2

Registration Number: NCT01117129

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy